Targeting Cyclin-Dependent Kinases in Cancer Treatment
Author Information
Author(s): Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J
Primary Institution: Institute for Cancer Research and Royal Marsden Hospital
Hypothesis
Targeting cyclin-dependent kinases (Cdks) may lead to selective cytotoxicity and valuable anticancer activity.
Conclusion
Newer and more specific Cdk inhibitors may result in decreased toxicity and more selective cytotoxicity in cancer treatment.
Supporting Evidence
- Dysregulation of the cell cycle is a hallmark of malignancy.
- Targeting Cdks has shown promise in clinical trials.
- Newer Cdk inhibitors are being developed to reduce side effects.
Takeaway
Scientists are trying to find ways to stop cancer cells from growing by targeting special proteins called cyclin-dependent kinases. This could help make cancer treatments safer and more effective.
Methodology
The review discusses various strategies and clinical trials involving pharmacologic Cdk inhibitors.
Limitations
The review does not provide specific data on the effectiveness of each Cdk inhibitor or detailed patient demographics.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website